Is T-DXd + Pertuzumab the New FirstLine Standard? – Drs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin

Playlist - Drs. Neil Iyengar, Komal Jhaveri, & Igor Makhlin

CLEOPATRA Explained: How It Became the First-Line Standard in HER2+ Breast Cancer

1 min read

DESTINY-Breast09: 40-Month PFS — A New First-Line Reality for HER2+ Disease?

1 min read

Frontline HER2+ Therapy: Why “Best Drug First” May Matter More Than Sequencing

1 min read

Managing T-DXd Toxicity: ILD, Nausea, Fatigue & What to Watch For

1 min read

Which HER2+ Patients Should Receive T-DXd + Pertuzumab First-Line?

1 min read

Supportive Care with T-DXd: Antiemetics, Fatigue & Hair Preservation

1 min read

Maintenance or Maximum Response? Rethinking Long-Term Control in HER2+ Disease

1 min read

After Frontline T-DXd: How Should HER2+ Disease Be Sequenced Next?

1 min read